Drug Trial Radar · NCT00443898
Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Last checked: Nov 19, 2026Latest source record: May 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
518
Actual
Start
Dec 2006
Primary completion
Jun 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Conditions
- Onychomycosis
Interventions
terbinafineDrug
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
PlaceboDrug
vehicle (placebo) applied once daily for 48 weeks
terbinafineDrug
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
PlaceboDrug
vehicle (placebo) applied once daily for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.Time frame: 52 weeks
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
Dr. Boni Elewski
Birmingham, Alabama
Dr. Stacy Smith
San Diego, California
Dr. James Swinehart
Denver, Colorado
Dr. David G. Armstrong
North Chicago, Illinois
Dr. Kevin Terry
Lutherville, Maryland
Dr. Anthony Puopolo
Milford, Massachusetts
Dr. John Fenyk
Chaska, Minnesota
Dr. Joel Schlessinger
Omaha, Nebraska
Dr. AnneMarie Uliasz
New York, New York
Dr. Willard Niemi
Raleigh, North Carolina
Dr. Diane Baker
Lake Oswego, Oregon
Dr. John Barnes
Portland, Oregon
Dr. Harry Penny
Altoona, Pennsylvania
Dr. Lawrence Parish
Philadelphia, Pennsylvania
Dr. Cynthia Strout
Mt. Pleasant, South Carolina
Dr. Teresa Coats
Austin, Texas
Dr. Scott J. Ashton
Dallas, Texas
Dr. Amit Pandya
Dallas, Texas
Dr. Lawrence Harkless
San Antonio, Texas
Dr. Robert Shouey
Harrisonburg, Virginia
Novartis Investigative Site
Various Cities, Canada
Novartis Investigative Site
Various Cities, Iceland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.